Q3 EPS Estimate for Abeona Therapeutics Increased by Analyst

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Abeona Therapeutics to a loss of $0.25 per share from $0.26, while maintaining a Buy rating and $20 price target. The analyst also projects a $1.15-per-share loss for fiscal 2026.
• Abeona’s latest quarterly results missed expectations, with an EPS loss of $0.35 versus the $0.23 consensus and revenue of $11.38 million compared with estimates of $12.24 million.
• Analyst sentiment remains mixed: the stock has a consensus Hold rating and $19.33 target price, while shares opened at $6.21. Insiders have sold $1.67 million worth of stock over the past 90 days, although institutional investors own 80.56% of shares.

Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) - Research analysts at HC Wainwright upped their Q3 2026 earnings estimates for Abeona Therapeutics in a note issued to investors on Monday, August 24th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of ($0.25) per share for the quarter, up from their prior estimate of ($0.26). HC Wainwright currently has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Abeona Therapeutics' Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.15) EPS, Q1 2027 earnings at ($0.20) EPS and FY2027 earnings at ($0.49) EPS.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.12). The firm had revenue of $11.38 million for the quarter, compared to analyst estimates of $12.24 million.

Several other brokerages have also issued reports on ABEO. Wall Street Zen raised Abeona Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 1st. Oppenheimer reiterated an "outperform" rating and issued a $21.00 price objective (down from $22.00) on shares of Abeona Therapeutics in a research report on Friday, August 14th. Finally, Weiss Ratings cut Abeona Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a report on Monday, August 17th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $19.33.

Abeona Therapeutics Stock Up 2.5%

Shares of ABEO opened at $6.21 on Wednesday. The business's fifty day moving average price is $6.40 and its two-hundred day moving average price is $5.62. The firm has a market capitalization of $355.09 million, a price-to-earnings ratio of -5.70 and a beta of 1.35. Abeona Therapeutics has a 52 week low of $4.00 and a 52 week high of $7.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.40 and a current ratio of 6.63.

Insider Activity at Abeona Therapeutics

In related news, SVP Brendan M. O'malley sold 12,050 shares of Abeona Therapeutics stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $6.96, for a total transaction of $83,868.00. Following the completion of the sale, the senior vice president directly owned 427,953 shares of the company's stock, valued at $2,978,552.88. The trade was a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Leila Alland sold 11,000 shares of the company's stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $5.92, for a total value of $65,120.00. Following the completion of the sale, the director owned 162,614 shares of the company's stock, valued at $962,674.88. This represents a 6.34% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 274,578 shares of company stock worth $1,674,433. 7.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors have recently modified their holdings of the stock. Pale Fire Capital SE increased its stake in shares of Abeona Therapeutics by 17.3% in the 2nd quarter. Pale Fire Capital SE now owns 81,945 shares of the biopharmaceutical company's stock valued at $506,000 after acquiring an additional 12,100 shares during the last quarter. Headlands Technologies LLC boosted its stake in Abeona Therapeutics by 97.5% during the 2nd quarter. Headlands Technologies LLC now owns 125,090 shares of the biopharmaceutical company's stock worth $773,000 after acquiring an additional 61,745 shares during the last quarter. AWM Investment Company Inc. bought a new position in Abeona Therapeutics during the 2nd quarter worth approximately $9,184,000. Bank of New York Mellon Corp acquired a new position in Abeona Therapeutics during the second quarter valued at approximately $1,262,000. Finally, Royal Bank of Canada grew its holdings in Abeona Therapeutics by 49.6% during the first quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 2,155 shares during the period. 80.56% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company's research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company's lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source